Small Molecules in Oncology from Emerging Companies: 2021’s IPOs Pt. III

This article is Part 3 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 2 provided an overview of 2021 IPOs by therapeutic area.

This short article takes a deeper look into the 2021 IPOs for conventional small molecules being developed by oncology-focused companies including:

  • Companies by asset class of focus and primary indication
  • Lead molecules, mechanisms of action, and structures where available
  • Development stage at IPO
  • IPO proceeds
  • A company spotlight

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.


RECENT ARTICLES

DRUG DISCOVERY RESOURCES

JOIN SUBSCRIBERS from

  • Johnson & Johnson
  • Roche
  • Pfizer
  • Novartis
  • Bayer
  • Merck
  • Sanofi
  • GlaxoSmithKline
  • AbbVie
  • Eli Lilly
  • Boehringer Ingelheim
  • Amgen
  • Bristol-Myers Squibb
  • Gilead
  • AstraZeneca
  • Teva
  • Novo Nordisk
  • Merck KGaA
  • Takeda
  • Celgene (BMS)
  • Biogen
  • Astellas
  • Daiichi Sankyo
  • Regeneron
  • UCB
  • Eisai
  • Servier
  • Kyowa Kirin
  • Shionogi
  • Vertex
  • Lundbeck
  • Taisho
  • Ono
  • Seagen
  • Incyte
  • LEO Pharma
  • Janssen
  • Galapagos
  • Idorsia
  • Astex
  • Arvinas
  • Kymera
  • Relay
  • Schrodinger
  • Mirati
  • Revolution
  • Nimbus
  • Plexxikon
  • Forma
  • Arcus
  • RA Capital
  • ARCH Venture Partners
  • MPM Capital
  • Orbimed
  • The Column Group
  • 5AM Ventures
  • Versant Ventures
  • Deerfield
  • Goldman Sachs
  • Citi
  • Piper Sandler
  • Softbank
  • …and hundreds of others